“Hi, Grandma. How’s that uncomfortable feeling in your stomach?”“I took the drug a doctor gave me last time, but I still feel nauseous and uncomfortable.”“It seems appropriate to go back to the doctor.”This conversation is an edited version of the process of managing the health of older adults livin
"Besponsa (inotuzumab ozogamicin) helps patients with relapsed or refractory acute lymphoblastic leukemia (ALL) with a poor prognosis undergo allogeneic stem cell transplantation under positive conditions by increasing the rate of complete remission and MRD-negative achievement compared to conventio
Korean researchers drew attention at the American Society of Clinical Oncology annual meeting, ASCO 2023, by presenting a variety of therapeutic strategies, including immunotherapies, which will contribute to improving the treatment landscape for significant and rare cancers.The Korea Cancer Study G
VUNO, a medical AI company, said Wednesday it has signed a business agreement with medical content platform company Weknew to develop a patient-centered healthcare industry using artificial intelligence.Under the agreement, the two companies will jointly develop various medical content targeted at p
Trends in diabetes treatment are changing rapidly.In its 2022 guideline, the American Diabetes Association (ADA) recommended that sodium-glucose cotransporter (SGLT)-2 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) be prescribed as early treatment for people with type 2 diabete
The nation’s health insurance review agency said Roche's Evrysdi (risdiplam), an oral treatment for spinal muscular atrophy (SMA), was deemed eligible for reimbursement. The decision came more than two years after Roche’s application.The Health Insurance Review and Assessment Service (HIRA) held the
Decentralized clinical trials (DCT) drew attention by playing a central role in developing Covid-19 vaccines.DCT is a new clinical trial technique attracting attention worldwide for its advantages compared to traditional clinical trials, such as easy patient recruitment, the convenience of conductin
In Korea, pneumococcal serotype “19A” is commonly found in infants under five to adults over 65. However, serotype “3” is more prominently observed in adults, according to a study.“Korea’s serotype distribution is completely different from that of other countries, such as the U.S., France, and Japan
AstraZeneca's Lynparza (olaparib), a poly ADP-ribose polymerase (PARP) inhibitor, has been added to the Korean Breast Cancer Society’s (KBCS) practice guidelines, two months after expanding its indication to postoperative adjuvant therapy in adult patients with breast cancer in Korea.Last month, the
The first real-world data (RWD) for Yuhan Corp.’s new lung cancer treatment Leclaza (lazertinib) in the second-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) in Korea has been released. The research team, led by Professor Lim Sun-min at the Oncology Division of Yonsei Ca
Exkivity (mobocertinib), Takeda’s targeted agent for EGFR (epidermal growth factor receptor) Exon 20 insertion mutation non-small cell lung cancer (NSCLC), will likely improve patients’ quality of life, too, an expert predicted.Professor Kim Tae-min of the Hemato-Oncology Department at Seoul Nationa
Spinal muscular atrophy (SMA) patients taking Spinraza (nusinersen) are protesting against the Health Insurance Review and Assessment (HIRA), claiming its review of reimbursement standards is inconsistent.A task force comprised of young SMA patients maintained Wednesday that an increasing number of
SD Biosensor, an in vitro diagnostic firm, is facing trouble at home and abroad.In April, the National Tax Service slapped a fine of about 100 billion won ($74.6 million) on SD Biosensor, and the U.S. Food and Drug Administration recently recommended suspending the use of the company’s Covid-19 diag
“A look at the diabetes drug prescription trends in the U.S. and Europe reveals the increase in the proportion of SGLT-2 inhibitors. Although the corresponding share is low in Korea now, it will become similar to America and Europe over time.”Professor Yang Yeo-ri of the Endocrinology Department at
For Abecma (idecaptagene vicleucel or ide-cel), BMS’ CAR-T cell therapy for multiple myeloma, to survive in the Korean market, it must devise an approval strategy differentiated from its competitor, Janssen’s Carvykti (ciltacaptagene autoleucel, or cilta-cel).Abecma’s globally approved indication as
Immunotherapies, mainly used for stage 4 treatments, are expanding their indications to pre- and postoperative treatments of earlier-stage lung cancer. Accordingly, the domestic immunotherapy market will grow even further.The combined sales of two such drugs – Opdivo (nivolumab) of Ono Pharma and BM
Non-small cell lung cancer (NSCLC) has been one of the areas the treatments of which have not drawn much attention. The biggest reason: finding lung cancer patients in the early stage was difficult.According to national cancer statistics, about 45 percent of Korean lung cancer patients are stage 4 p
Novo Nordisk Korea said it received the Ministry of Food and Drug Safety’s approval for Wegovy Prefilled Pen (ingredient: semaglutide) on Thursday last week. Wegovy, a once-weekly treatment for obesity, is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight m
Beigene Korea said Monday that its Brukinsa Capsule 80mg (zanubrutinib) began to receive insurance benefits to treat Waldenstrom Macroglobulinemia (WM) starting this month.The new reimbursement standard applies to Brukinsa’s monotherapy in adult WM patients who have received one or more treatments.B
“Targeted agents have long dominated the breast cancer treatment market, but the initiative is now shifting to antibody-drug conjugate (ADC) therapies.”Professor Kim Kwon-cheon, a surgeon at Chosun University Hospital, said so during the GBCC (Global Breast Cancer Conference) 2023 at Grand Walker Hi